Clinical course of IPF in Italian patients during 12 months of observation: results from the FIBRONET observational study

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

DOI

  • V. Poletti, Morgagni-Pierantoni Hospital
  • ,
  • C. Vancheri, University of Catania
  • ,
  • C. Albera, University of Turin
  • ,
  • S. Harari, University of Milan, IRCCS Multimedica - Milano
  • ,
  • A. Pesci, Azienda Ospedaliera San Gerardo Monza
  • ,
  • R. R. Metella, University of Siena
  • ,
  • B. Campolo, Boehringer Ingelheim GmbH
  • ,
  • G. Crespi, Boehringer Ingelheim GmbH
  • ,
  • S. Rizzoli, MediNeos Observational Research
  • ,
  • the FIBRONET study group

Background: FIBRONET was an observational, multicentre, prospective cohort study investigating the baseline characteristics, clinical course of disease and use of antifibrotic treatment in Italian patients with idiopathic pulmonary fibrosis (IPF). Methods: Patients aged ≥ 40 years diagnosed with IPF within the previous 3 months at 20 Italian centres were consecutively enrolled and followed up for 12 months, with evaluations at 3, 6, 9 and 12 months. The primary objective was to describe the clinical course of IPF over 12 months of follow-up, including changes in lung function measured by % predicted forced vital capacity (FVC% predicted). Results: 209 patients (82.3% male, mean age 69.54 ± 7.43 years) were enrolled. Mean FVC% predicted was relatively preserved at baseline (80.01%). The mean time between IPF diagnosis and initiation of antifibrotic therapy was 6.38 weeks; 72.3% of patients received antifibrotic therapy within the first 3 months of follow-up, and 83.9% within 12 months of follow-up. Mean FVC% predicted was 80.0% at baseline and 82.2% at 12 months, and 47.4% of patients remained stable (i.e. had no disease progression) in terms of FVC% predicted during the study. Conclusions: FIBRONET is the first prospective, real-life, observational study of patients with IPF in Italy. The short time between diagnosis and initiation of antifibrotic therapy, and the stable lung function between baseline and 12 months, suggest that early diagnosis and prompt initiation of antifibrotic therapy may preserve lung function in patients with IPF. Trial registration: NCT02803580

OriginalsprogEngelsk
Artikelnummer66
TidsskriftRespiratory Research
Vol/bind22
Nummer1
Antal sider9
ISSN1465-9921
DOI
StatusUdgivet - feb. 2021

Bibliografisk note

Funding Information:
The FIBRONET study was funded by Boehringer Ingelheim International GmbH.

Funding Information:
BC was an employee of Boehringer Ingelheim (Italy) at the time of this study. GC is an employee of Boehringer Ingelheim. SR is an employee of MediNeos Observational Research (Modena, Italy). AP has received personal (speaker/advisory board) fees from Boehringer Ingelheim and Roche, and his research activity is partially supported by project Premia. SH has acted as a clinical trial investigator, participated in scientific advisory boards, and delivered lectures for Boehringer Ingelheim, Roche and Actelion. He has also received research grants from Boehringer Ingelheim. CA has acted as a clinical trial investigator for Boehringer Ingelheim and Roche, participated in scientific advisory boards for Boehringer Ingelheim, Roche, MSD, Fibrogen and GSK, and received research grants from Boehringer Ingelheim and Roche. CV has received research grants and personal fees from Boehringer Ingelheim and Roche. VP has received personal fees from Boehringer Ingelheim. RRM has nothing to disclose.

Publisher Copyright:
© 2021, The Author(s).

Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.

Se relationer på Aarhus Universitet Citationsformater

ID: 213444418